Search Results - "Groo, Vicki L."

Refine Results
  1. 1

    Automatic Errors: A Case Series on the Errors Inherent in Electronic Prescribing by Lourenco, Laura M., Bursua, Adam, Groo, Vicki L.

    “…ABSTRACT The adoption of electronic prescribing is on the rise, as it reduces medication errors compared to handwritten orders. The inadvertent dispensing of…”
    Get full text
    Journal Article
  2. 2

    LEVERAGING OUR STRENGTHS: CLINICAL PHARMACIST MEDIATED PCSK9 UTILIZATION by Groo, Vicki L, Ardati, Amer, Stubbings, Jo Ann

    “…Background: Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors were approved by the FDA in 2015 for patients with atherosclerotic cardiovascular…”
    Get full text
    Journal Article
  3. 3

    HEART FAILURE HOTLINE AS AN INNOVATION TO ADDRESS MEDICATION ISSUES by Groo, Vicki L, Schuetz, Rebecca, Dickens, Carolyn, Vuckovic, Karen, Gans, Christopher, Stamos, Thomas

    “…Physicians, nurses, pharmacists, Nurse Practitioners (NP) dieticians, physical therapists, and social workers each have their own office or contact…”
    Get full text
    Journal Article
  4. 4

    Concomitant use of levofloxacin and fluconazole leading to possible torsades de pointes by Tilton, Jessica J, Sadr, Rozhan, Groo, Vicki L

    Published in Journal of oncology pharmacy practice (01-12-2019)
    “…Prolongation of the corrected QT interval can lead to the deadly arrhythmia torsades de pointes. There are many risk factors for corrected QT prolongation, one…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Use of a Simplified Nomogram to Individualize Digoxin Dosing versus Standard Dosing Practices in Patients with Heart Failure by DiDomenico, Robert J., Bress, Adam P., Na-Thalang, Kwanta, Tsao, Yvonne Y., Groo, Vicki L., Deyo, Kelly L., Patel, Shitalben R., Bishop, Jeffrey R., Bauman, Jerry L.

    Published in Pharmacotherapy (01-11-2014)
    “…Study Objectives To compare the frequency of achieving a therapeutic serum digoxin concentration (SDC), defined as 0.5–0.9 ng/ml, by using a simplified…”
    Get full text
    Journal Article
  7. 7

    Association of Aldosterone Concentration and Mineralocorticoid Receptor Genotype with Potassium Response to Spironolactone in Patients with Heart Failure by Cavallari, Larisa H., Groo, Vicki L., Viana, Marlos A. G., Dai, Yang, Patel, Shitalben R., Stamos, Thomas D.

    Published in Pharmacotherapy (01-01-2010)
    “…Study Objective. To identify patient‐specific factors associated with spironolactone‐induced potassium level elevation in patients with heart failure. Design…”
    Get full text
    Journal Article
  8. 8

    Clopidogrel Adherence following Percutaneous Coronary Intervention with a Drug-Eluting Stent in a VA Medical Center by Shroff, Adhir, Ali, Ambreen, Groo, Vicki L

    Published in The Journal of pharmacy technology (01-05-2009)
    “…Background: Antiplatelet therapy with aspirin and a thienopyridine is the standard of care for prevention of thrombosis following coronary stent implantation…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Association of β-Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure by Cavallari, Larisa H., Momary, Kathryn M., Groo, Vicki L., Viana, Marlos A. G., Camp, Joseph R., Stamos, Thomas D.

    Published in Pharmacotherapy (01-06-2007)
    “…Study Objective. To determine whether β‐blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in…”
    Get full text
    Journal Article
  17. 17

    Racial differences in potassium response to spironolactone in heart failure by Cavallari, Larisa H, Groo, Vicki L, Momary, Kathryn M, Fontana, Deidra, Viana, Marlos Ag, Vaitkus, Paul

    “…Evidence of racial differences in aldosterone concentrations and K+ disposition suggests that response to aldosterone antagonism might vary by race. The…”
    Get more information
    Journal Article
  18. 18

    Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure by Cavallari, Larisa H, Groo, Vicki L, Momary, Kathryn M, Stamos, Thomas D, Vaitkus, Paul T

    “…Cardiac fibrosis plays an important role in the pathophysiology of heart failure. The authors sought to determine whether biomarkers of cardiac fibrosis for…”
    Get more information
    Journal Article
  19. 19

    Racial Differences in Patients' Potassium Concentrations During Spironolactone Therapy for Heart Failure by Cavallari, Larisa H., Fashingbauer, Lucy A., Beitelshees, Amber L., Groo, Vicki L., Southworth, Mary R., Viana, Marlos A. G., Williams, Randall E., Dunlap, Stephanie H.

    Published in Pharmacotherapy (01-06-2004)
    “…Study Objective. To determine whether the effects of spironolactone on potassium homeostasis vary by race by comparing serum potassium concentrations and…”
    Get full text
    Conference Proceeding Journal Article
  20. 20